Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models

Cyclin-dependent kinases, CDK4 and CDK6, are essential in regulating the cell cycle, which is disrupted in cancers like isocitrate dehydrogenase wild-type glioblastoma (GBM). Currently marketed CDK4/6 inhibitors, including abemaciclib, have shown preclinical efficacy in solid tumors, but factors suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Lei, Yao, Zhenglin, Wang, Yue, Mazuranic, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403987/
https://www.ncbi.nlm.nih.gov/pubmed/36033522
http://dx.doi.org/10.3389/fonc.2022.915862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403987/
https://www.ncbi.nlm.nih.gov/pubmed/36033522
http://dx.doi.org/10.3389/fonc.2022.915862

Ejemplares similares